Clomipramine capsules failed a degradation product specification at expiry testing
Clomipramine Hydrochloride Capsules USP 25 mg are being recalled after an out of specification result for an unspecified degradation product during retention sample testing at expiry. 2,724 bottles affected.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall for an out-of-specification degradation result found at expiry, with no named impurity or health consequence stated.
Plain-English summary
Clomipramine Hydrochloride Capsules USP, 25 mg, 100 count bottles, NDC 68180-492-01, are being recalled. The action covers 2,724 bottles.
The stated reason is failed impurities and degradation specifications: an out of specification result was observed in the degradation product test for any unspecified degradation product during retention sample testing at expiry. The FDA classified the action as Class II. The source does not name the degradation product or state a health consequence.
The affected lot is M300464, expiring June 2025. Distribution was nationwide.
Patients holding the affected lot should speak to their pharmacist or prescriber before stopping treatment, and pharmacies should follow the instructions issued by the manufacturer.
The recalled product
- Product
- CLOMIPRAMINE HYDROCHLORIDE (CLOMIPRAMINE HYDROCHLORIDE CAPSULES)
- Brand
- CLOMIPRAMINE HYDROCHLORIDE
- Manufacturer
- Lupin Pharmaceuticals Inc.
- Category
- Drug — Oral capsule
- Affected units
- 2,724
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot # M300464
- exp. date June
- 2025
UPCs (2)
- 0368180494065
- 0368180493068
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · CLOMIPRAMINE HYDROCHLORIDE
- HighClomipramine 50 mg capsules recalled over nitrosamine above the intake limit
FDA (Drugs) · 2025-11-12
- HighClomipramine 25 mg capsules recalled over nitrosamine above the intake limit
FDA (Drugs) · 2025-11-12
- HighClomipramine 75 mg capsules recalled over nitrosamine above the intake limit
FDA (Drugs) · 2025-11-12
- ModerateClomipramine Hydrochloride Capsules recalled for degradation product specification failure
FDA (Drugs) · 2025-04-30
- HighAntidepressant Medication Recalled for Excessive Active Ingredient Potency
FDA (Drugs) · 2022-10-05
Same manufacturer · Lupin Pharmaceuticals Inc.
See all →- ModerateLupin Recalls Clobetasol Propionate Cream for Content Uniformity Failures
FDA (Drugs) · 2026-09-02
- SevereGlucagon Emergency Kit Recalled for Manufacturing Process Deviation
FDA (Drugs) · 2026-07-08
- HighPrednisolone Acetate Ophthalmic Suspension Recalled for Foreign Substance
FDA (Drugs) · 2026-07-08
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- ModerateGanirelix acetate injection recalled after failing an impurity specification
FDA (Drugs) · 2025-12-17
Same hazard · degradation product
See all →- LowPitavastatin tablets recalled for failed impurities and degradation specifications
FDA (Drugs) · 2025-07-09
- ModerateCephalexin Oral Suspension Recalled for Failed Impurity Specifications
FDA (Drugs) · 2025-06-18
- ModerateCephalexin Oral Suspension Recalled for Failed Impurities Specifications
FDA (Drugs) · 2025-06-18
- LowEzetimibe and Simvastatin Tablets Recalled for Failed Impurity Specifications
FDA (Drugs) · 2025-06-18
- SevereEsomeprazole Magnesium Oral Suspension Recalled for Failed Impurity Specifications
FDA (Drugs) · 2025-05-28